Private Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Private Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,729	Closed	-$903K	–	299
2026 Q1	$903K	Buy	2,729 +574	+27%	+$195K	0.06%	159
2025 Q4	$857K	Buy	2,155 +736	+52%	+$326K	0.07%	137
2025 Q3	$647K	Buy	+1,419	New	+$578K	0.05%	144
2023 Q1	–	Sell	-3,351	Closed	-$796K	–	201
2022 Q4	$796K	Buy	3,351 +146	+5%	+$31.1K	0.17%	101
2022 Q3	$642K	Buy	+3,205	New	+$611K	0.15%	111

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Advisory Group's ALNY Position: Q2 2026 in Review

Private Advisory Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 2,729 shares — an estimated $903K sold.

Private Advisory Group first reported a position in ALNY in Q3 2022 and held it in 5 quarters. The position peaked at $903K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Private Advisory Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Private Advisory Group sold 2,729 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $903K.
Private Advisory Group first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Private Advisory Group's Alnylam Pharmaceuticals position peaked at $903K in Q1 2026.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Private Advisory Group's 13F filing for Q2 2026, filed 6 Aug 2026.